Genentech to present blood disorders data at ASH

Genentech, a member of the Roche (RHHBY), announced that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology, or ASH, annual meeting and exposition, held December 7-10 in San Diego, California. The data underscore Genentech’s commitment to advance patient outcomes in lymphoma with long-term follow-up of its approved medicines Polivy, Lunsumio and Columvi as well as new investigational combination data. Five-year data from the Phase III POLARIX study reinforce the potential of Polivy in combination with Rituxan, cyclophosphamide, doxorubicin and prednisone to provide durable and lasting remissions and for the first time show a positive trend in overall survival, or OS, for people with first-line diffuse large B-cell lymphoma, or DLBCL, an area that previously had little advancement in nearly two decades. Extended follow-up data of up to four years from the pivotal GO29781 study of Lunsumio and NP30179 study of Columvi show long-lasting remissions and immune system recovery after the end of treatment, supporting the use of fixed-duration bispecific antibodies for third-line or later follicular lymphoma and DLBCL, respectively. First presentation of data for a subcutaneous formulation of Lunsumio monotherapy from the pivotal Phase II GO29781 study show high rates of deep and durable responses and low rates and severity of cytokine release syndrome in people with 3L+ FL. Subcutaneously administered Lunsumio could further improve the patient experience by combining shorter administration time with the existing benefits of a fixed-duration and outpatient therapy. New patient-reported outcomes data from the Phase III STARGLO study indicate comparable health-related quality of life between treatment arms, despite higher median number of cycles received with the Columvi combination. Together with the significant improvement in OS observed in the study, these data support the potential benefit for patients with second-line or later DLBCL. New and updated data from investigational study combinations of Polivy with bispecific antibodies Lunsumio and Columvi in relapsed or refractory DLBCL, including the Phase Ib/II NP39488 and Phase II GO40516 studies, add to the growing body of evidence demonstrating the potential of novel bispecific antibody/Polivy combinations in earlier treatment lines, and support their ongoing Phase III development.